Epitalon and MOTS-c questions
Some questions have a specific experimental answer. For human use, the gaps in safety and efficacy are still substantial.
What does MOTS-c do?
Its preclinical record includes improved physical performance in mice, muscle glucose uptake and atrophy prevention in mouse models and stress-responsive gene regulation in human and mouse cells. MOTS-c is also made by the body. The human blood-marker findings concern that endogenous peptide; benefit from administering it has not been established.
Does Epitalon lengthen telomeres?
Yes, in the cultured human fetal fibroblasts in the 2003 study and the human cell lines studied in 2025. The latter work found different routes in normal and breast-cancer lines, including significant ALT activity in the cancer lines. No source here measured telomere lengthening in a living person.
What about sleep?
Sleep improvement is a recurring Epitalon anecdote, alongside accounts of no noticeable change. Those accounts are anecdotal reports rather than clinical evidence. The melatonin-synthesis experiment used rat pineal cells in culture; it did not measure sleep in people. Human sleep testing would make that connection far more persuasive.
Human dosing and cycling
There is no established human dosing standard for either peptide and no published, validated human pharmacokinetic basis for calculating one. Animal quantities and cell-culture concentrations are experimental conditions in those settings. They supply no reliable conversion into a personal dose, frequency or cycle.
I cannot answer a dosing request from this evidence. The same applies to combining the compounds, choosing an injection route or predicting when an effect would be felt.
What are the side effects?
For MOTS-c, a controlled human adverse-effect profile is missing. For Epitalon, long-term human safety remains unresolved; the telomerase and ALT findings in cell lines raise cancer-related questions, and the 2025 overview describes incomplete characterisation.
Epitalon community accounts mention injection-site irritation, drowsiness, vivid dreams, headache or lightheadedness as well as no effect. They are uncontrolled anecdotes, with unverified causation. A list assembled from those accounts cannot establish incidence or safety.
Are they approved medicines?
Research-labelled MOTS-c is sold for laboratory study, not human consumption; MOTS-c has no FDA approval for any use. Epitalon has no FDA, EMA or MHRA approval and no registered indication. Prescribing through Promise Peptides (mypromise.com) is an individual clinical decision; research-labelled material is still sold for laboratory work and is not intended for human consumption. The parent extract Epithalamin has had limited clinical use in Russia for specific indications; that history does not confer approval on synthetic Epitalon.
Can athletes use them?
Anti-doping authorities treat MOTS-c as prohibited in elite sport, and athlete use can result in sanctions. The existing Epitalon record describes it as not specifically listed on the WADA Prohibited List as of that review, while noting that peptide classifications are revised periodically. A historical review cannot establish an athlete's current eligibility.
Has either extended human life?
Neither has established an extension of human lifespan in a randomised, placebo-controlled trial. The long human follow-up used Epithalamin and was observational. The Epitalon survival result in female SHR mice increased maximum lifespan with mean lifespan unchanged. The MOTS-c studies here report physical function and biological mechanisms rather than a survival benefit.